INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

Successful, productive infection of human cells by adenoviruses involves a complex interplay between the induction and suppression of apoptosis (43a). Proteins encoded by early region 1A (E1A) transactivate early viral gene expression and stimulate cells to enter S phase to enhance viral DNA synthesis. One consequence of E1A expression by human adenovirus type 5 (Ad5) is the stabilization of p53 (11, 29) resulting from complex formation with members of either the retinoblastoma tumor suppressor or the p300/CBP families of cell cycle regulators (8, 42). Adenoviruses prevent apoptosis or growth arrest by p53 through the action of two E1B products, the 55-kDa protein that binds to and inhibits p53 (51, 58) and the 19-kDa polypeptide that suppresses apoptosis via a mechanism analogous to the cellular Bcl-2 protein (6, 18). The turnover of p53 is also enhanced through the action of complexes between the Ad5 E1B 55-kDa protein and a product of E4, E4orf6 (13, 41). In addition, E1A enhances cell susceptibility to killing by tumor necrosis factor (14, 46, 57), an effect that is also inhibited by the E1B 19-kDa protein (38, 40) as well as E3 products (reviewed in reference 53).

In previous studies it was noted that E1B-defective Ad5 also induces apoptosis in p53-null cells through the transactivation of another early viral product (52) that was subsequently mapped to E4, which encodes seven polypeptides (30). Using a series of Ad5 E4 mutants, we identified E4orf4 as the E4 product that induces p53-independent apoptosis (31). These studies indicated that the expression of Ad2 E4orf4 alone in the absence of other viral products results in p53-independent cell death. Similar results have been obtained by another group (46a). Furthermore, we established cell lines expressing Ad2 E4orf4 under an inducible promoter and showed that such cells die rapidly upon induction, exhibiting classic apoptotic features, including DNA degradation, chromatin condensation, and the presence of phosphatidylserine on the outer cell membrane as determined by annexin V staining (28). We believe that one of the roles of E4orf4 may be to cooperate in the killing of infected cells at the end of the infectious cycle. An E4orf4-null mutant was originally described as being more cytotoxic than the wild-type virus, as mutant-infected cells were observed to detach from the plastic dishes at early times (35); however, we found that such cells were still viable and survived longer than those infected by the wild-type virus (31). Mutants defective in the E3-11.6K protein also exhibit a similar phenotype (54), and thus, this protein may cooperate with E4orf4 in cell killing. Apoptosis is a mechanism used by a number of viruses as the host inflammatory response is diminished, and progeny are protected from host antibodies and proteases because they are released in apoptotic membrane-bound vesicles (reviewed in references 43a and 50).

The biological activity of E4orf4 was first revealed through studies showing a synergistic effect on transcription factor AP-1 by E1A products and cyclic AMP (15, 16, 36). Under these conditions E4orf4 caused a decrease in phosphorylation of both the E1A protein and c-Fos, the latter causing decreased AP-1 transcriptional activity. The kinetics of this effect implied that E4orf4 was acting to inhibit a cellular kinase involved in phosphorylation of these proteins (35). E4orf4 was additionally shown to suppress JunB and c-Fos protein production at both transcriptional and translational levels (35). A major insight came with the discovery that E4orf4 associates with the B subunit of cellular protein phosphatase 2A (PP2A) (26). The effects of E4orf4 on AP-1 are believed to be caused by PP2A-dependent dephosphorylation and inactivation of a mitogen-activated protein kinase, which can act as a PP2A substrate and is believed to play a role in the regulation of AP-1 (1, 4, 17, 22). This effect also has direct implications in the regulation of E4 gene expression, which is dependent on transcription factor E4F, which in turn is activated by E1A-induced phosphorylation (2, 3, 43). E4orf4 inhibits E4 expression, but treatment with okadaic acid, an inhibitor of PP2A, results in upregulation, suggesting that E4orf4-induced PP2A activity may cause the dephosphorylation of E4F (2). We have also identified two mitogen-activated protein kinase-dependent sites in the E1A protein that must be phosphorylated for E1A-mediated activation of expression of E4 but not of E3 (56). This form of autoregulation may limit the levels of E4orf4 and thus prevent early cell death. In addition, the E4orf4-PP2A complexes appear to induce the hypophosphorylation of SR splicing factors involved in spliceosome assembly and splice site recognition, to promote usage of a secondary splice site required for late viral gene expression (25).

PP2A is an abundant cellular serine/threonine phosphatase which exists as a trimer of the C catalytic subunit and A and B regulatory subunits. The A subunit is a 65-kDa rodlike protein comprised of 15 nonidentical repeats (7, 20, 27, 55). The catalytic C subunit is a 37-kDa protein that binds to repeats 11 to 15, whereas B subunits bind to repeats 1 to 10 of the A subunit (7, 20, 23, 24, 27, 33, 44, 45, 55). Thus far, about 20 B-subunit variants have been cloned and exist in three classes. The B class comprises at least four members of about 55 kDa, termed B, B, and B (19, 39a, 47a, 60, 61). The B' (B56) class contains at least 13 isoforms (10, 33, 34, 48, 49, 59). The B" class contains two forms produced by alternative splicing of about 72 and 130 kDa (21). The various B subunits, which share limited or no homology, are believed to function not only in defining the substrate specificity of the PP2A holoenzyme (5) but also in intracellular targeting, in tissue specificity, and as binding partners for interacting proteins and second messengers. PP2A targets in mammalian and yeast cells include proteins involved in basal metabolism, DNA replication, cell proliferation, and cell cycle regulation (9). Substrate specificity is altered considerably depending on the form of B subunit in the holoenzyme (12, 32, 47). The AC (core) dimer is also present in cells at reasonable levels but seems to lack substrate specificity (27). Complex formation with the B subunit increases core phosphatase activity (60). As described above, E4orf4 may bind selectively to the B subunit (26), although interactions with other B subunits have not been rigorously tested.

In the present study we have used a genetic approach to determine if binding of E4orf4 to the B subunit is required for E4orf4-induced p53-independent apoptosis. Our results from using a large series of point mutants indicated that such is clearly the case. However, there is a second class of mutants that exhibit reduced cell killing, even though they are able to bind the B subunit at high levels. Thus, although binding to PP2A is essential for inducing p53-independent apoptosis, E4orf4 may possess one or more additional functions required for killing.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

Cell lines. Human C33A (ATCC HTB-31) and H1299 cells (ATCC CRL-5803), which are both deficient in p53 expression, were cultured in Falcon tissue culture dishes in -minimal essential medium (Bio-Whittaker) supplemented with 10% fetal bovine serum (Bio-Whittaker), 100 U of penicillin and streptomycin/ml, and 0.292 mg of L-glutamine/ml.

Plasmids. A cDNA expressing Ad2 E4orf4 (39) was subcloned into the mammalian expression vector pcDNA3 (Invitrogen) by using BamHI-XhoI digestion to produce pcDNA3-E4orf4. The E4orf4 sequence was excised from pcDNA3-E4orf4 by using PCR with the additional introduction of flanking BamHI (5') and EcoRI (3') sites. The forward oligonucleotide was GC GGA TCC ATG GTT CTT CCA GCT C, and the reverse oligonucleotide was CGA ATT CTA CTG TAC GGA GTG (both 5' to 3'). The digested PCR product was cloned into a pcDNA3 variant in which a hemagglutinin (HA) epitope tag had been previously inserted upstream of the multicloning cassette. This process fused the HA tag to the 5' end of the E4orf4 sequence with glycine and serine residues between them, producing pcDNA3-HAE4orf4. The final product was confirmed by DNA sequencing. cDNAs expressing E4orf4 from other adenovirus serotypes were cloned as follows. For those from Ad9, Ad12, and Ad40, the E4orf4 coding region was cloned from virally infected KB cells by PCR using published sequences of the E4 regions, adding 5' BamHI and 3' EcoRI sites for cloning into pcDNA3. For Ad3 and Ad4, the region between the fiber coding sequence and the inverted terminal repeat was cloned by PCR and the entire region was sequenced. Sequences encoding E4orf4 were then cloned by PCR and inserted into pcDNA3 as above.

Mutant construction. As we found that the products of most E4orf4 deletion mutants were highly unstable when expressed in mammalian cells (data not shown), E4orf4 deletion mutants were made as fusion products with HA-tagged maltose binding protein (HA-MBP) present at the amino terminus. Various in-frame deletions and carboxy-terminal truncations were created by using PCR in the E4orf4 coding sequence. The E4orf4 point mutant alanine substitutions were generated by using standard three-oligonucleotide PCR-based mutagenesis with pcDNA3-E4orf4 as the template. As described above, BamHI and EcoRI sites were inserted at either end of the coding sequence and the PCR products were cloned into the pcDNA3 construct with the HA epitope. All mutants were confirmed by DNA sequencing. The point mutants were named by using the original residue code, the residue location, and then the substituted residue code.

Protein expression. To verify protein expression from wild-type and mutant E4orf4 plasmids, Lipofectamine PLUS (Gibco-BRL) was used together with 1.25 µg of plasmid DNA and lipofected into 60-mm plates of H1299 or C33A cells. Cell extracts were prepared in a volume of 100 µl at 24 h postlipofection (0.1% Nonidet P-40 [IGEPAL; Sigma], 0.4 M KCl, 50 mM HEPES [pH 7.9], 10% glycerol, 0.2 M EDTA, 1 mM dithiothreitol, and 0.5 mM phenylmethylsulfonyl fluoride). Protein levels were quantified using the Bio-Rad protein assay reagent, and 10 µg of total protein per lane was resolved by sodium dodecyl sulfate-15% polyacrylamide gel electrophoresis (SDS-15% PAGE). Separated proteins were transferred to nitrocellulose and probed with mouse anti-HA antibody (HA.11; BAbCO) at a 1/2,500 dilution. Visualization was completed using a goat anti-mouse immunoglobulin G Fc fragment-specific antibody linked to horseradish peroxidase (Jackson ImmunoResearch) at a 1/100,000 dilution followed by enhanced chemiluminescence (ECL) detection (NEN Life Science Products). Protein expression was in some cases also quantified using an ¹²⁵I-conjugated secondary antibody with HA.11, followed by analysis using a Fuji phosphorimager.

Preparation of construct expressing a FLAG-tagged B subunit. The DNA sequence encoding the B subunit of PP2A was excised from pPP2A55(7-1) (39a) by using PCR with the additional introduction of flanking KpnI (5') and EcoRI (3') sites. The forward oligonucleotide was CGG GGT ACC GTC GAC TAT GGC AGG AGC TGG AGG AGG G, and the reverse oligonucleotide was CGA ATT CTA ATT CAC TTT GTC TTG AAA TAT ATA C (both 5' and 3'). The digested PCR product was cloned into a pcDNA3 variant in which the FLAG epitope tag had been previously inserted upstream of the multicloning cassette. This placed the FLAG tag at the 5' end of the B sequence, followed by six residues from the cloning cassette (Ser-Leu-Val-Pro-Ser-Thr) and then the B coding region, to produce pcDNA3-FLAGPP2AB. The final product was confirmed by DNA sequencing.

PP2A assay. Phosphatase activity was assessed following the introduction of 1.25 µg of wild-type or mutant pcDNA3-HAE4orf4 together with 1.25 µg of pcDNA3-FLAGPP2AB into 60-mm plates of H1299 or C33A cells using Lipofectamine PLUS (Gibco-BRL). One milliliter of cell extracts prepared in 50 mM Tris-HCl (pH 7.5) containing 0.5% IGEPAL, 0.1% Triton X-100, 250 mM NaCl, and 5 mM EDTA was clarified and immunoprecipitated using 2 µl of HA.11 together with protein A Sepharose CL-4B beads (Pharmacia Biotech). The immunoprecipitated complexes were washed three times with extraction buffer, washed twice with 20 mM MOPS (morpholinepropanesulfonic acid) (pH 7.5) containing 60 mM -mercaptoethanol, 0.1 M NaCl, and 0.1 mg of bovine serum albumin/ml, and were then assayed for phosphatase activity with the malachite green-based Ser/Thr phosphatase assay kit (UBI). A synthetic phosphopeptide containing a generic PP2A consensus site (KRpTIRR) was used as the substrate.

E4orf4-PP2A binding assay. The immunoprecipitates prepared as described above were separated by SDS-8% PAGE. Proteins were transferred to nitrocellulose and were then probed with the M2 mouse anti-FLAG antibody (Kodak/Sigma-Aldrich) at a dilution of 1/1,000. Proteins were visualized by using a goat anti-mouse immunoglobulin G F(ab')₂ fragment-specific antibody linked to horseradish peroxidase (Jackson ImmunoResearch) at a 1/100,000 dilution, followed by ECL detection (NEN Life Science Products).

E4orf4 cell death assays. Wild-type or mutant pcDNA3-HAE4orf4 (0.45 µg) was introduced into H1299 or C33A cells at 50% confluence in 12-well plates using Lipofectamine PLUS (Gibco-BRL). Two days after transfection the cells were trypsinized and 1/100 of the cells in each well was replated in each of three 60-mm plates. The cells were cultured in the presence of 750 µg of G418 (Gibco-BRL)/ml for 2 weeks to select for neomycin-resistant cell growth, as pcDNA3 contains the neo resistance marker. At the end of this period, the cells were trypsinized and viable cells were counted with a hemocytometer. In some experiments, cell colonies were fixed in methanol-acetic acid (3:1), stained with 0.15 mg of Giemsa stain/ml of phosphate-buffered saline, and scored visually.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

Analysis of cell killing by E4orf4 products of different adenovirus serotypes. It was shown previously that E4orf4 interacts with the B subunit of PP2A (26) and that this interaction leads to decreased phosphorylation of adenovirus E1A products (26, 56), c-Fos (35), transcription factor E4F (2), and SR proteins (25). These results suggested that the association of E4orf4 with PP2A may either activate or redirect the activity of this phosphatase. To determine if such interactions are also required for E4orf4-induced p53-independent apoptosis (28, 30, 31, 52), a genetic approach was used to define the regions of E4orf4 involved in these functions. Furthermore, we wanted to determine if E4orf4 regions apart from those required for PP2A binding were involved in cell killing. As a first approach, the E4orf4 products encoded by several classes of human adenoviruses were tested, as they represent a series of natural E4orf4 mutants. Figure 1 shows that considerable homology exists among E4orf4 products of different groups of human adenoviruses, with differences evident primarily at the carboxy terminus. cDNAs containing E4orf4 coding sequences from representative members of each adenovirus group were cloned by PCR from viral genomic DNA and fused with a sequence encoding an HA epitope tag. Such cDNAs were used in colony inhibition assays similar to those of a previous study (31), in which the killing of transfected human H1299 lung carcinoma cells was measured by the reduction in colony formation following selection with G418 (as described in Materials and Methods). Figure 2 shows that although Ad2 E4orf4, (group C) was the most efficient at reducing colony formation, Ad4 E4orf4, (group E), Ad9 E4orf4, (group D), Ad12 E4orf4, (group A), and Ad40 E4orf4 (group F) all yielded substantially fewer colonies than control cells transfected with pcDNA3 DNA alone. Thus, all of these E4orf4 molecules appeared to induce cell death with similar efficiencies, suggesting that highly conserved residues within the E4orf4 coding sequences may be of particular importance in the killing potential of E4orf4. The clear exception was Ad3 E4orf4 (group B), which exhibited no colony inhibitory activity. Western blotting analysis using anti-HA antibody indicated that the level of expression of Ad3 E4orf4 was considerably lower than that of the other adenovirus E4orf4 products (Fig. 2, bottom). As discussed below and elsewhere in more quantitative studies (R. C. Marcellus, H. Chang, D. Paquette, D. Boivin, G. C. Shore, and P. E. Branton, unpublished data), it appears that the expression of a certain critical level of E4orf4 is required to induce significant cell death. Thus, either Ad3 E4orf4 was defective for cell killing, or its level of expression was insufficient. As the promoter constructs used to express all of the E4orf4 products were identical, it is likely that the Ad3 E4orf4 protein may be more unstable than the products of other serotypes.

View larger version (68K): [in this window] [in a new window]   FIG. 1.   E4orf4 coding sequence for different human adenovirus serotypes. The protein sequences for members of various classes of human adenoviruses are presented. The alignment was performed by using the CLUSTAL V multiple-sequence-alignment algorithm (21a) and Gene Inspector (Textco Inc.). The score is based on amino acid identity.

View larger version (45K): [in this window] [in a new window]   FIG. 2.   Cell killing by various adenovirus E4orf4 proteins. H1299 cells were lipofected with plasmid DNA expressing neo and wild-type or mutant E4orf4 and then trypsinized, replated, and allowed to grow in the presence of G418. The results represent the averages of two separate experiments, each involving three plates per sample. The standard error in such experiments was less than 30% (top). At the time of replating, some cells were examined for E4orf4 expression by Western blotting using anti-HA antibodies (bottom).

Analysis of PP2A B-subunit binding using E4orf4 deletion mutants. Deletion mutagenesis was attempted as an approach to study E4orf4 interactions with the B subunit. Initial mutants containing amino- or carboxy-terminal truncations and 10 to 15 amino acid internal deletions in the Ad2 E4orf4 protein largely yielded highly unstable products when expressed in mammalian cells (data not shown). To avoid such problems, deletion-containing and truncated E4orf4 coding sequences were constructed as fusion products with HA-MBP (i.e., HA-MBP-Ad2 E4orf4), as illustrated in Fig. 3A. cDNAs encoding these HA-tagged mutant E4orf4 products were cotransfected into cells along with a construct expressing a FLAG-tagged B subunit. Figure 3C shows that in all cases, high levels of expression were obtained, as determined by Western blotting analysis of whole-cell extracts using anti-HA antibody. Cell extracts were immunoprecipitated with anti-HA antibody; following separation by SDS-PAGE, proteins were transferred and analyzed by Western blotting using anti-FLAG antibody to determine the level of binding of the B subunit. Figure 3B shows that the levels of binding with all mutants were extremely low or undetectable in comparison to those observed with full-length E4orf4 or MBP-E4orf4. The highest levels of B-subunit binding among the mutants were with constructs expressing only residues 80 to 100 (A80/T100) and 80 to 114 (A80/Q114), suggesting that residues 80 to 100 may be involved in the interaction with the B subunit; however, the deletion of residues 11 to 39 (dl11-39) eliminated binding, suggesting that this region may be required for the interaction in some fashion. These data suggested that maintenance of the integrity of the E4orf4 protein is critical for efficient complex formation with the B subunit and that the E4orf4 protein structure is not tolerant of large-scale alterations. In addition, none of these deletion constructs was capable of inducing significant cell death in colony inhibition assays similar to those shown in Fig. 2 (data not shown), suggesting that deletion analysis is of limited value in analyzing the structure and function of E4orf4.

View larger version (39K): [in this window] [in a new window]   FIG. 3.   Analysis of B-subunit binding by E4orf4 deletion mutants. A series of E4orf4 deletions were produced and expressed as fusion products with HA-MBP, as described in Materials and Methods. Such DNA constructs were lipofected into H1299 cells along with a cDNA expressing a FLAG-tagged human B subunit. Aliquots of the cell extracts were immunoprecipitated with anti-HA antibody. After SDS-PAGE and transfer, they were immunoblotted with anti-FLAG antibody to detect associated B binding. Other aliquots were separated directly by SDS-PAGE and after transfer were immunoblotted with anti-HA antibody to detect levels of HA-MBP-E4orf4 expression. (A) Map of E4orf4 deletion mutants; (B) B-subunit binding; (C) HA-MBP-E4orf4 expression in whole-cell extracts (WCE).

Construction of E4orf4 point mutants. The alignments shown in Fig. 1 for E4orf4 from different adenovirus serotypes were used to identify highly conserved residues that were then targeted for mutagenesis. Thus, a series of HA-tagged single-point mutants as well as some groupings of point mutants for Ad2 E4orf4 was produced, all with alanine substitutions (Fig. 4). To verify that these mutants were stably expressed at high levels, corresponding cDNAs were introduced by lipofection into H1299 cells. Figure 5 shows that most of these mutants yielded high levels of stable products comparable to those obtained with wild-type E4orf4. The only exceptions were mutants L3A and P7A/P9A/P10A, which were shown by quantitative immunoblotting using ¹²⁵I-labeled antibody to be expressed at less than one-third of wild-type levels. These mutants therefore were excluded from the present study. Protein expression levels were also determined in the human cervical carcinoma line C33A. Some differences in stability were evident between H1299 and C33A cells, which are discussed further, below.

View larger version (39K): [in this window] [in a new window]   FIG. 4.   Summary of Ad2 point mutants. A series of E4orf4 point mutants were produced as described in Materials and Methods. The residues below the bar are the sites for a series of single-point mutations. Above the bar are the locations of mutations for multiple-point mutants. Single-letter amino acid codes were used to show the original residue, and all mutants were constructed with alanine substitutions.

View larger version (50K): [in this window] [in a new window]   FIG. 5.   Analysis of B-subunit binding and associated phosphatase activity of E4orf4 mutants. H1299 cells were lipofected with the HAE4orf4 mutants together with FLAG-tagged B. Cell extracts were prepared 24 h postlipofection, and anti-HA immunoprecipitations were performed. Immunoprecipitates were assayed for PP2A activity using a synthetic phosphopeptide as the substrate, as described in Materials and Methods, and results of the average of four separate experiments were plotted relative to those for wild-type E4orf4, which were set at 100% (top). The standard error in these assays was less than 30%. Immunoprecipitates (IP) or whole-cell extracts (WCE) were separated by SDS-PAGE, transferred to nitrocellulose, and then immunoblotted against the FLAG epitope to determine B-subunit levels. In addition, blots containing whole-cell extracts were immunoblotted to detect the level of HAE4orf4 by using a murine anti-HA monoclonal antibody. Results from one of four such studies are presented.

Association of the B subunit and PP2A activity with E4orf4 mutant proteins. E4orf4 binds to the B subunit of the PP2A holoenzyme, which also contains the catalytic C and A subunits (reviewed in reference 37). Such binding has been shown to link E4orf4 to the PP2A holoenzyme (26). The abilities of wild-type and mutant E4orf4 proteins to associate with functional PP2A activity were determined in H1299 cells which had been colipofected with cDNAs expressing exogenous FLAG-tagged B and HA-tagged E4orf4. In the present and previous studies (31), no evidence that these molecular tags have any effect on the biological activities of E4orf4 or the B subunit has been detected. Cell extracts were immunoprecipitated with anti-HA antibodies, and the precipitates were then resuspended in reaction buffer and assayed in vitro for phosphatase activity by using a synthetic peptide containing a universal phosphoserine phosphatase substrate site. Phosphate release was determined spectrophotometrically using a malachite green-based assay. Figure 5 shows that high levels of phosphatase activity were present in precipitates containing wild-type E4orf4, indicating that the HA tag did not interfere with the association with PP2A. Figure 5 also shows that the expression of the B subunit was comparable in all cell extracts. For most of the mutants, the level of phosphatase activity was similar to that present with wild-type E4orf4; however, a number of mutants were defective in coprecipitating active phosphatase, including L51/54A, R69A/R70A/R72/73/74/75A, R81A/F84A, K88A/Y89A, and Y89A, and to some extent, C18A, T64A/E65A/R66A, R73/74/75A, and F84A. As expected, these levels of phosphatase activity corresponded well to the quantities of FLAG-B bound to E4orf4 as detected by immunoblotting (Fig. 5), suggesting that these nine mutants were either partially or almost completely defective in binding to the B subunit. The analyses of binding of B in these and previous (46b) studies were only semiquantitative because of the use of the ECL method of detection. Thus relative phosphatase levels were used in further correlations as quantitative measurements of the interaction of E4orf4 with the B of PP2A. This approach provides a more quantitative estimate of B binding, and our extensive analyses have indicated that the binding of E4orf4 has no effect on PP2A activity against this universal substrate (data not shown). It was noted that the apparent correlation between phosphatase activity and B binding (Fig. 5) of two mutants, F84A and R93/94A, appeared to be somewhat at variance. It should be remembered that the phosphatase data were derived from four separate experiments, whereas the binding data represented a single Western blotting analysis which may not be representative of all experiments. For both of these mutants, other analyses indicated somewhat higher levels of binding of B, in keeping with the phosphatase activities presented in Fig. 5.

Correlation between B binding and induction of cell death using E4orf4 mutants. To determine the importance of B binding in the induction of cell death, colony formation was assessed following the lipofection of H1299 cells with plasmid DNA coexpressing wild-type or mutant E4orf4 and the neo marker and selection by G418. In such experiments, the number of colonies obtained with wild-type E4orf4 was arbitrarily set at 100. The mean colony formation index derived from four separate experiments, each containing three plates per mutant, was determined. The overall variation for each analysis in such studies was about 30%. Most of the mutants inhibited colony formation to about the same extent as wild-type E4orf4; however, with several mutants a considerable increase in the number of colonies was noted, thus indicating reduced cell killing. To correlate cell killing determined in these experiments with the binding of the B subunit, relative cell viability (i.e., colony-forming ability) was plotted against the phosphatase activity found to be associated with each mutant E4orf4 protein. Figure 6 indicates that for most mutants, the inhibition of colony formation was similar to that of wild-type E4orf4. This effect was seen not only with mutants that associated efficiently with PP2A but also with three or four mutants that bound less than 60% of wild-type levels. Remarkably, mutants F84A and C18A associated with only 25 and 34% of wild-type levels yet still killed as well as or better than the wild type. These results suggested that cell killing was induced if binding exceeded a critical lower threshold. Nonetheless, most mutants that associated with lower amounts, including L51/54A, R69A/R70A/R72/73/74/75A, R81A/F84A, K88A/Y89A, and Y89, were greatly defective for killing. These have been termed class I mutants (Fig. 6 and Table 1). Two additional mutants, T64A/E65A/R66A and R73/74/75A, which associated with PP2A at less than 34% of wild-type levels and were considerably defective in killing, are probably also class I mutants that interact at levels lower than the threshold. These results indicated that a reduction in association with PP2A blocks cell killing and thus links PP2A binding to the induction of apoptosis. A second class of mutants was also apparent, including W21A, L51A, R81A, K88A, and R93/94A, in which substantive levels of PP2A binding were evident but cell killing was greatly impaired. These mutants have been termed class II mutants. Five additional mutants displayed more modest reductions in cell killing yet interacted with PP2A normally, including P9A, I43A, L54A, R55A, and D99A. These results suggested that although PP2A binding was necessary for the induction of cell killing, it was not sufficient.

View larger version (26K): [in this window] [in a new window]   FIG. 6.   Analysis of cell killing versus associated phosphatase activity for E4orf4 mutants. The ability of E4orf4 mutants to associate with PP2A and to kill H1299 cells was assessed. The number of colonies and phosphatase activity detected with wild-type (wt) E4orf4 were arbitrarily set at 100. Class I mutants that failed to bind and to induce cell death are indicated in a box at the top left, whereas class II mutants that bound B but failed to kill efficiently are indicated in a box at the top right. Mutants that may be of the class II type are presented in the box bordered by dotted lines. The experimental error in each of these assays was less than 30%.

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

E4orf4 products encoded by most if not all human adenovirus serotypes are highly efficient in inducing cell death. It is our belief that one part of this function is to play a role in the death of infected cells at the late stage of lytic infection.

Figure 7 summarizes the results of our genetic analysis of E4orf4 function. The present results demonstrate that PP2A binding is clearly necessary for induction of cell death by E4orf4. This possibility was also suggested in a recent study, but that work employed a smaller number of E4orf4 mutants and semiquantitative analysis (46b). In the present study, all E4orf4 class I mutants that failed to bind B and associate with PP2A activity were highly defective for induction of cell death. This genetic approach suggested that a region in E4orf4 including residues 51 to 89 may be of some importance in binding of the B subunit. This region could be involved directly in binding or could represent a portion of the E4orf4 molecule that regulates binding at another site; however, class I mutants were not found in any other regions. Analysis of E4orf4 deletion mutants suggested that residues 80 to 100 may be directly involved in binding, and two class I mutations, K88A/Y89A and Y89A, as well as a class II mutation, R93/94A, were identified in this region. These possibilities were also strengthened by the results of a previous study, which showed that mutants containing S95P and G19A/N103I mutations had phenotypes similar to those of our class I mutants, as did mutant R55A/E56A/W57A/C78R (46b). It should be noted that one of the class II mutations, W21A, is located within residues 11 to 39, which were shown by using deletion mutants to play a role in binding when the amino terminus of E4orf4 is present. Further detailed, structural information will be required to assess this situation. Nonetheless, binding to PP2A is clearly essential for cell killing by E4orf4.

View larger version (46K): [in this window] [in a new window]   FIG. 7.   Summary of E4orf4 residues involved in PP2A binding and cytotoxicity. The mutations that gave rise to E4orf4 proteins deficient in cell killing, PP2A binding, or both are indicated. E4orf4 is shown binding to the PP2A B subunit.

The other important outcome of the present study was the identification of the class II mutants that bind the B subunit at normal levels but are defective for killing. These results suggested that association with PP2A is necessary but not sufficient for killing. It is unclear whether this additional requirement implies a function distinct from B binding or if it reflects the need for a highly precise interaction between B and E4orf4. For example, a class II mutant E4orf4 protein may be competent to interact with and remain bound to B during the isolation and immunoprecipitation procedures but fail to exert a biological effect on PP2A. Apart from W21A, class II mutants were found close to and sometimes immediately adjacent to residues shown in class I mutants to be required for binding. In addition, although mutants L51A and L54A were individually of the class II type, when the mutations were present in combination (i.e., L51/54A) the mutant was class I. These observations suggest but do not prove that the class II mutants may fail to kill because the binding which they exhibit is not sufficiently exact to exert a biological effect. Again, structural analysis could resolve this issue.

What might be the consequences of the interaction between B and E4orf4? A reasonable interpretation of earlier work on E4orf4 is that binding activates PP2A activity (16, 26, 35, 36). Although we have not noted any overall change in PP2A activity against the universal peptide substrate as a consequence of interaction with E4orf4, it is highly possible that E4orf4 alters activity against specific substrates that are normally regulated by the B subunit. The other possibility is that E4orf4 provides an additional function required for cell killing, such as altering the intracellular localization of PP2A, altering the binding of other B-interacting proteins, or linking PP2A with critical substrates. Such effects on PP2A would not be detected in the present in vitro assays. Studies to address these possibilities are under way.